美國食品藥物管理局新藥核准對那斯達克生技股異常報酬影響之研究

Translated title of the contribution: The Impact of FDA New Drug Approval on Abnormal Return of Nasdaq Biotech Stock

陳柏昌

Research output: Types of Thesis › Master's thesis

Translated title of the contributionThe Impact of FDA New Drug Approval on Abnormal Return of Nasdaq Biotech Stock
Original languageChinese (Traditional)
Supervisors/Advisors
  • Shyu, Yih-Wen, Supervisor
StatePublished - 2009
Externally publishedYes

Access to Document

Cite this